StockNews.com assumed coverage on shares of Pulmatrix (NASDAQ:PULM – Get Rating) in a research report released on Monday. The firm issued a hold rating on the biotechnology company’s stock.
Pulmatrix Stock Down 1.1 %
Shares of NASDAQ:PULM opened at $4.40 on Monday. Pulmatrix has a 1-year low of $4.03 and a 1-year high of $20.80. The firm’s 50 day simple moving average is $4.69 and its two-hundred day simple moving average is $5.90.
Pulmatrix (NASDAQ:PULM – Get Rating) last released its earnings results on Thursday, May 12th. The biotechnology company reported ($1.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.41) by ($0.10). Pulmatrix had a negative net margin of 426.00% and a negative return on equity of 37.38%. The firm had revenue of $1.16 million for the quarter, compared to analysts’ expectations of $1.07 million. On average, sell-side analysts anticipate that Pulmatrix will post -6.04 EPS for the current fiscal year.
Institutional Trading of Pulmatrix
Pulmatrix Company Profile
Pulmatrix, Inc, a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Read More
- Get a free copy of the StockNews.com research report on Pulmatrix (PULM)
- Use These To Find Your Stock’s Support and Resistance Levels
- Is Boeing Stock is Ready for Lift-Off ?
- Elon Musk is Out, But Should You Be In Twitter Stock?
- 3 Earnings Announcements That Could Surprise
- Twitter’s Up For Third Week In A Row: What’s Next For The Stock?
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.